Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., has appointed Dr. Richard Woodman as Chief Clinical Officer of its Oncology Business Group. In this role, Dr. Woodman will oversee the strategic and operational leadership of the company’s global oncology clinical development functions, including clinical research, clinical operations, imaging, medical writing, data services, biostatistics and regulatory strategy. He will also serve as a member of the Oncology Executive Lea...